Reuters logo
BRIEF-Regeneron and Sanofi announce positive phase 2 study results for dupilumab
October 16, 2017 / 12:06 PM / a month ago

BRIEF-Regeneron and Sanofi announce positive phase 2 study results for dupilumab

Oct 16 (Reuters) - SANOFI:

* REGENERON AND SANOFI ANNOUNCE POSITIVE PHASE 2 STUDY RESULTS FOR DUPILUMAB IN PATIENTS WITH ACTIVE MODERATE-TO-SEVERE EOSINOPHILIC ESOPHAGITIS

* ‍THESE POSITIVE PHASE 2 RESULTS SUPPORT FURTHER CLINICAL DEVELOPMENT OF DUPILUMAB FOR PATIENTS WITH EOSINOPHILIC ESOPHAGITIS.​

* ‍STUDY SHOWED PATIENTS WHO RECEIVED DUPILUMAB WEEKLY REPORTED SIGNIFICANT IMPROVEMENT IN ABILITY TO SWALLOW VERSUS PLACEBO​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below